High levels of protein expression are key to the successful development and manufacture of a therapeutic antibody. Here, we describe two related antibodies, Ab001 and Ab008, where Ab001 shows a markedly lower level of expression relative to Ab008 when stably expressed in Chinese hamster ovary cells. We use single-gene expression vectors and structural analysis to show that the reduced titer is associated with the V L CDR2 of Ab001. We adopted two approaches to improve the expression of Ab001. First, we used mutagenesis to change single amino-acid residues in the Ab001 V L back to the equivalent Ab008 residues but this resulted in limited improvements in expression. In contrast when we used an in silico structure-based design approach to generate a set of five individual single-point variants in a discrete region of the V L , all exhibited significantly improved expression relative to Ab001. The most successful of these, D53N, exhibited a 25-fold increase in stable transfectants relative to Ab001. The functional potency of these V L -modified antibodies was unaffected. We expect that this in silico engineering strategy can be used to improve the expression of other antibodies and proteins.
Introduction
Monoclonal antibodies are an economically important class of therapeutic against cancer, infectious and autoimmune diseases (Ecker et al., 2015; Reichert, 2015) . With many new antibodies entering clinical development, attention is focused on the factors that impact commercial potential, such as the ability to produce sufficient quantities of the drug to meet patient need, ease of administration and cost, as well as clinical efficacy and safety. Production cost and manufacturing capacity requirements are determined by yields from the manufacturing process. Typically, antibodies are produced from stable recombinant Chinese hamster ovary (CHO) or murine myeloma cell lines (Walsh, 2014) . Antibody yields from these systems have been maximized by optimizing vector and cell line engineering combined with media and process development to achieve titers of up to 10 g/l in fed-batch bioreactor processes (Estes and Melville, 2014) . However, not all antibodies achieve such high titers and this is at least in part determined by the antibody sequence itself (Pybus et al., 2014a, b) . Consequently, during lead isolation and optimization, expression along with other developability parameters is screened empirically in order to select antibodies with suitable characteristics for manufacture. Typically, transient gene expression (TGE) is used for rapid production of microgram to milligram amounts of antibodies for early stage characterization (Jäger et al., 2015) . There is a general correlation between expression levels observed in transient and stable production systems (Diepenbruck et al., 2013) and so this TGE also serves as an expression screen. In this study, we have advanced the empirical expression screening approach to apply sequence and structural analysis with in silico design tools to engineer improved antibody production yields whilst maintaining potency.
IL-13 is a Th2 cytokine that has been implicated in multiple inflammatory and fibrotic diseases, such as asthma (Wills-Karp, 2004) , ulcerative colitis (Mannon and Reinisch, 2012) and idiopathic pulmonary fibrosis (Maher, 2012) . As a result of its central role in airway inflammation and remodeling, IL-13 has been identified as a potential target for therapeutic antibodies for the treatment of asthma, and a number of anti-IL-13 monoclonal antibodies are currently undergoing late-stage clinical development (Pelaia et al., 2012; Piper et al., 2013; Hanania et al., 2015) .
Developability of a new drug is dependent on a wider set of molecular attributes to facilitate both the manufacturing process and drug delivery (Yang et al., 2013) , including stability, expression, chemical modifications and solubility. Moreover, some of these attributes can be highly challenging to optimize in drug development and manufacturing, for example requiring experimental testing to overcome any technical hurdles and ensure the ease of production. On the other hand, other such attributes can be tackled computationally, such as by sequence analysis, structure-sequence relationship analysis, molecular modeling, protein docking and molecular dynamics (MD) with structure analysis. These approaches are used to identify residues that may be modified during drug discovery and development, such as by the oxidation of methionine and tyrosine and deamination of aspartic acid as well as asparagine isomerization. However, chemical modifications can affect protein expression, functional activity, molecular stability and the quality of the product. Mitigation strategies may be required if these modifications are located in the complementarity-determining regions (CDRs), where they are likely to affect biological function (Haberger et al., 2014) .
Computational rational design approaches for improving antibody expression have not been reported; however, there are reports in the literature of using rational sequence optimization to improve antibody developability (Seeliger et al., 2015) . Specifically, the authors of this paper were focused on mitigating antibody tendency to precipitate in vitro. In this paper, we use structure-guided design approaches to understand and mitigate antibody expression challenges. Although structure-based design approaches have been used to address a variety of challenges in the antibody drug discovery process (Shirai et al., 2014) , in this report, we use computational strategies based on protein structure analyses, such as protein structure, surface electrostatics and protein dynamics analyses to address antibody expression challenges for the first time to our knowledge. The work described here might represent a generic methodology for identifying problematic residues that affect expression and ultimately impair manufacturing yields.
In this study, we used transient expression in CHO cells (Daramola et al., 2014) to assess the physicochemical, affinity and potency characteristics of two anti-IL-13 antibodies, Ab001 and Ab008. Subsequently, stably transfected CHO pools and clonal cell lines were constructed to provide larger amounts of antibody for pre-clinical and clinical development. We show for both transient and stable systems that the observed expression levels of Ab001 were notably lower than those of the Ab008 antibody. We were interested in increasing the expression levels of Ab001 to the comparable levels observed with Ab008. To achieve this we employed a structure-based approach that identified the amino acids responsible for the reduced expression level, and identified a single amino-acid substitution that successfully restored expression.
Materials and methods

Phage display and binding assays
Ab008 was isolated from a human scFv (V H -V L ) phage display library derived from spleen lymphocytes (Hutchings C et al., 'Generation of Naïve Human antibody libraries', in Antibody Engineering, R. Kontermann and S. Dübel Editors 2001 Springer Laboratory Manuals) (Lloyd et al., 2009) . Several rounds of selection on recombinant IL-13, covalently coupled to paramagnetic beads, or biotinylated and then captured on streptavidin-coated beads (Vaughan TJ et al., Nat. Biotech. (1996) 14 (3), 309-314) were performed. A proportion of the clones from the output were sequenced. Unique clones were assessed for their ability to neutralize IL-13 in an IL-13-dependent proliferation assay.
Ab008 was affinity matured using phage display and targeted mutagenesis of V H and V L CDRs using NNS randomization. Optimized blocks from phage display libraries were recombined and selected on decreasing concentrations of biotinylated antigen (Groves et al., 2014) . Error prone PCR and ribosome display was also employed to explore diversity in regions of the variable region that would not have been targeted by the block randomization strategy. Ab001 was identified as an improved Ab008 variant following this in vitro affinity maturation strategy, using a biochemical receptor-ligand inhibition assay and screening as IgG in a TF1 proliferation assay.
Creating reversion mutants and structural mutants
Oligo-directed mutagenesis (Kunkel et al., 1987) was used to individually revert each of the amino-acid changes back to parental sequence in nine independent mutagenesis reactions. The codons for the original residues in Ab001 and the reverted residues are presented in Table I . The mutagenesis reaction was transformed into Zcompetent Escherichia coli DH5ɑ cells [supE44, ΔlacU169 (ϕ80 lacZ ΔM15)hsdR17 recA1 endA1 gyrA96 thi-1 relA1] prepared in house using Zymo Research Mix & Go TM transformation kit and buffer set (CA, USA). Transformed cells were plated onto to selective agar plates. After overnight growth, a small number of colonies were picked from each transformation for sequence verification. Nine sequence-confirmed 'reversion' mutants were then assessed for expression as IgG in transient cell lines. Two of the 'reversion' mutants (M27I and E52G) exhibited improved expression. Another round of oligo-directed mutagenesis (Kunkel et al., 1987) was performed. This time, the two mutants that had shown improved IgG expression (M27I and E52G) were combined to look for synergistic improvements in IgG expression (two primers were incorporated into one mutagenesis reaction to generate the 'M27I + E52G' mutant). Additional primers to incorporate the changes in V L CDR2 highlighted by the structure-based design approach were also synthesized. These were D51N, E52N and D53N. M27I was also combined with E52N in a single oligo-directed mutagenesis reaction (Kunkel et al., 1987) to investigate any potential synergy between these two amino-acid changes. Once again mutagenesis reactions were transformed into Zcompetent DH5ɑ cells (Zymo Research) and colonies grown on selective agar plates were picked for sequence verification. This, second panel of mutants was then expressed as IgG in transient cell lines.
Transient expression and quantitation of antibodies
Separate heavy-chain (IgG1) and light-chain mammalian expression plasmids were used for transient transfection as described previously (Persic et al., 1997) except that the vectors were modified to contain the Epstein-Barr virus origin of replication. DNA was added to 150 mM NaCl and 25 kDa linear polyethyleninime (PEI; Polysciences Europe, Hirschberg an der Bergstrasse, Germany), according to the manufacturer's recommendations. The DNA-PEI complex was then used to transfect CHO cells as described previously (Daramola et al., 2014) . After 7 days, the cells were harvested by centrifugation, and the supernatants were filtered. Titers were determined using antihuman IgG quantitation biosensors and the Octet 384QK (Pall ForteBio, Portsmouth, UK). The samples were diluted 1:5 in binding buffer to reduce matrix effects and analyzed according to the manufacturer's instructions. A standard curve was run alongside the samples to calculate the titers from supernatant samples. IgGs were purified from culture supernatants using ÄKTAxpress (GE Healthcare, Amersham, UK) and 1 ml MabSelect Sure columns (GE Healthcare, Amersham, UK). IgGs were eluted from the columns using 0.1 M sodium citrate (pH 3.0) and buffer-exchanged into phosphate-buffered saline (PBS) using PD10 columns (GE Healthcare, Amersham, UK). IgG in cell culture supernatants was quantified by protein-A HPLC affinity chromatography on an Agilent HP1100 or HP1200 (Agilent Technologies, Santa Clara, CA, USA) by comparing the peak size from each sample with a calibration curve.
High-Performance size exclusion chromatography
Purified IgGs were analyzed by high-performance size exclusion chromatography (HP-SEC) using an Agilent 1100 series HPLC fitted with a TSK SW XL HPLC guard column (Tosoh Bioscience, cat. 08543) and TSK-GEL G3000SW XL HPLC column (Tosoh Bioscience, cat. 08541). A 50 μl of IgG at 1 mg/ml in Dulbecco's PBS (D-PBS) (SigmaAldrich) was injected at a flow rate of 1 ml/min using 0.1 M sodium phosphate, 0.1 M sodium sulphate, pH 6.8 as the mobile-phase buffer. Protein elution was detected by monitoring absorbance at 280 nm. A gel filtration standard (Bio-Rad) and a standard antibody control were also run for QC and comparative purposes.
Thermodynamic stability measurement by differential scanning fluorescence Thermodynamic stability of the purified IgGs was measured using differential scanning fluorescence (DSF) as described by Goldberg et al. (2011) . Purified IgG's were used at a concentration of 0.5 mg/ml.
SYPRO
® Orange (Fisher Scientific, Loughborough, UK) was added at a 1:5 dilution in a total volume of 25 μl in a PCR plate. A Chromo4 Real Time PCR Detector (Bio-Rad, Hemel Hempstead, UK) was used as a thermal cycler and the fluorescence emission was detected using Opticon Monitor v2.03 software. The melting temperature (T m ) was calculated by the software using a mathematical second derivative method to calculate the inflection point of the curve. The reported T m is an average of two measurements.
Stable expression of antibodies
Stable CHO pools expressing human IgG1 molecules were generated by transfecting CHO suspension cells (Medimmune, Cambridge, UK) with a Medimmune expression plasmid using an Amaxa nucleofection system and reagents (Lonza, Slough, UK). The stable expression vector was modified from the transient expression vectors (Persic et al., 1997; Daramola et al., 2014) and contained both the antibody Hc and Lc genes in addition to the GS selectable marker gene (Lonza, Slough, UK). The transfected cells were selected and maintained in proprietary medium in the presence of 50 µM methionine sulfoximine (Sigma-Aldrich, Dorset, UK). Pools of cells were expanded and used for antibody production in a 14-day fed-batch process using proprietary medium. The medium was supplemented with bolus additions of a Medimmune proprietary nutrient feed added over the course of the culture period.
TF1 proliferation assay to assess relative mutant antibody potency
Human erythroleukaemia TF1 cells (R&D Systems) were washed three times in culture media (RPMI-1640 glutamax (Invitrogen), 5% heat-inactivated fetal bovine serum, 1% sodium pyruvate (Sigma), 1% penicillin/streptomycin (Invitrogen)) and then resuspended to a final concentration of 2 × 10 5 cells/ml in the same culture media.
Approximately 100 μl of cell suspension were dispensed into each well of a 96-well, flat-bottomed plate. In a separate plate, antibodies were titrated from 66 nM in 5-fold dilutions to 170 pM and incubated for 30 min at room temperature with human recombinant IL-13 (Peprotech) at a final concentration of 20 ng/ml. Approximately 100 μl of the antibody/cytokine mixture was added to the cell suspension. IL-13 alone and media alone served as positive and negative controls, respectively. Cells were cultured for 3 days at 37°C and 5% CO 2 . After this culture period, plates were pulsed with 0.2 μCi/well of tritiated thymidine (GE LifeSciences) for 4 h at 37°C and 5% CO 2 . Cells were then harvested onto glass fiber filter plates and dried. Approximately 50 μl of scintillate (Microscint, PerkinElmer) was dispensed onto each well of the filter plates, the filter platers were sealed and the thymidine incorporation was determined using a liquid scintillation counter (Topcount, PerkinElmer) and expressed as counts per minute. 
Protein modeling and MD methods
Using the antibody modeling protocol in Accelrys Discovery Studio (Fasnacht et al., 2014) (Accelrys Software Inc., Discovery Studio Modeling Environment, Release 4.0, San Diego: Accelrys Software Inc., 2013), the homology model of the antibody Fv structure was built by searching, assembling and optimizing the closest structural templates of CDRs, framework and V H -V L orientation. The distribution of the surface charge on the structural model of the Fv light chain was calculated using the APBS tools (Baker et al., 2001) provided in PyMOL, with default parameters (The PyMOL Molecular Graphics System, version 1.7.3 Schrödinger, LLC). The 'calculate mutation energy' protocol in Discovery Studio was used to perform single Asn mutations on V L CDR2 and measure the energy difference in stability. The mutation energies were calculated based on a static structural model. MD simulations were designed and conducted using GROMACS software (version 4.6.5) (Hess et al., 2008) . All of the simulations employed an Amber99sb-ildn force field (Lindorff-Larsen et al., 2010) and Tip4p-Ew water model to define atomic interactions (Horn et al., 2004) . After solvating the light chain of the antibody model into a water box with counter-ions (Na + ), the entire system was equilibrated at constant temperature and pressure (300 K, 1 bar) conditions for 1 ns. The same setup process was also applied to the light chain of the antibody model with the D53N substitution. Subsequently, a 200 ns production run was conducted for both systems. To challenge the structural stability of the protein, an additional pair of simulations with temperatures set at 500 K was performed. Both high-temperature simulations lasted 200 ns. The 'g_rms' command in GROMACS was used to calculate the V L CDR2 RMSD changes during the simulation. For each snapshot, we aligned the light-chain framework region to that of its starting configuration, and the deviations in the V L CDR2 region were measured.
Results
The light chain is responsible for the low expression of Ab001
To isolate a panel of anti-IL-13 antibodies, we performed phage display experiments using human IL-13 as antigen. The affinity maturation campaign had comprehensively targeted the heavy chain variable region via saturation mutagenesis and CDR walking. Ab001 was the product of an additional optimization campaign (unpublished data) that focused primarily on the light-chain CDRs, targeting the L1, L2 and L3 CDRs as well as H1 using phage display mutagenesis libraries built on a derivative of Ab008 with improved K D . The closest V H germline gene for Ab008 (and all subsequent variants, including Ab001) is V H 1-18 and the closest V L germline gene is V lambda 3_3h. After reformatting from scFv to IgG, we conducted experiments to screen for higher affinity binding and biological potency, which produced the final optimized antibody (hereafter referred to as Ab001).
To continue the drug discovery process, we assessed the developability of Ab001, as described for other monoclonal antibodies (Yang et al., 2013) . We expressed Ab001 by transient and stable transfectant pools in CHO cells. The expression of Ab001 was unexpectedly low, with the stable and transient expression of Ab001 at 3 and 35.8% that of the transient and stable Medimmune control antibodies (tMCA and sMCA) used as standards in our developability studies, respectively (Fig. 1) . By comparison, there appeared to be no significant loss of monomer due to antibody aggregation or fragmentation for Ab001 when compared to Ab008, as measured by HP-SEC, or any significant difference in thermostability between the two antibodies, as measured by DSF (Table II) .
Ab001 differs from parent Ab008 by seven amino acids in the V H and nine amino acids in the V L . We therefore firstly asked whether the low expression of Ab001 was associated with its V L or its V H , or a combination of both. We performed transient transfections with Ab001 heavy and light-chain plasmids in combination with each other in CHO cells. We also performed transient transfections with heavy and light chain of the tMCA antibody, the V H and V L of Ab008 or an unrelated IgG1. All antibodies had lambda light chains. For the unrelated IgG1, we used an anti-nerve growth factor monoclonal antibody (NGF mAb). The tMCA, anti-NGF and Ab008 antibodies exhibit good expression levels in CHO cells. The transient expression level for Ab001 was lower, at~66% of tMCA (Fig. 2) . The expression levels for the tMCA were reduced tõ 10.5% when the Ab001 V L , instead of the tMCA V L , was transfected with the tMCA V H . Its expression was reduced to~79% when the tMCA V L was transfected with the Ab001 V H . A 56% reduction in expression was also observed for NGF mAb when anti-NGF V H was combined with Ab001 V L , but the expression levels were not affected when Ab001 V H and anti-NGF V L were transfected together. Finally, Ab008 V H , when combined with Ab001 V L instead of Ab008 V L , resulted in the expression levels that werẽ 75% that of Ab008, and when Ab001 V H and Ab008 V L were transfected together, the expression levels were 76% that of Ab008. This reduction in expression with the Ab001 V H may have been due to variability of the replicates, 1 value was lower than the others, leading to a mean reduction of 76%. Although the lower expression of Ab008 was less marked when paired with Ab001 V L than with either tMCA or anti-NGF V L , taken together, these data indicate that the V L and not the V H causes the low expression of Ab001.
Cells expressing Ab001 were analyzed to better understand the underlying molecular basis of the observed expression limitation. The Ab001 V L sequence used in both transient and stable expression had been sequence-optimized to enhance CHO cell expression (Fath et al., 2011) , but to ensure that no unintended cryptic splice sites had been introduced and were impacting the transcript to limit light-chain expression (Wijesuiya et al., 2013) , the light-chain transcript sequence from stable cell lines was confirmed by cDNA sequencing (data not shown). During stable cell line development for Ab001, compared to a reference antibody of known expression (the anti-NGF mAb), there were both lower numbers of transfectants and lower levels of expression. For Ab001 QRT-PCR analysis indicated that the levels of light-chain transcripts were similar to the anti-NGF mAb, as was the level of intracellular light chain assessed by western blot, but the level of Ab001 free light chain was substantially reduced. Similarly, in Ab001 transients, there was a marked reduction in the level of secreted light chain (data not shown). Together these data suggested that the Ab001 light-chain limitation was post-translational as observed with some other antibodies (Mason et al., 2012; Reinhart et al., 2014) .
To determine whether the individual nine amino-acid differences between Ab008 and Ab001 V L were contributing to the observed differences in expression, we individually mutated nine variant amino acids in Ab001 to those that are present in Ab008, namely M27I, V28I, A30S, R31K, I47V, V48I, F49Y, E52G, S95aD. Following successful mutagenesis, the nine IgG mutant constructs were evaluated by transient CHO expression. Two of the mutants exhibited small increases in expression: E52G and M27I (Fig. 3) , although not equivalent to the levels of Ab008. Thus, further improvement in expression was desirable and so we next adopted a structure-based design approach that would help us to better understand the differences in protein structure between Ab008 and Ab001 and indicate changes to Ab001 that could ameliorate this expression difference.
Structural analysis of charged V L CDR2
Our data indicated that the low expression of Ab001 was linked to its light chain. To explore this at the structural level, we made a homology model of the Ab001 Fv region based on its amino-acid sequence. Figure 4a depicts the structural model, with all of the lightchain CDRs highlighted. A careful inspection of the CDRs indicates that the sequence and conformation of V L CDR2 are typical. However, although the loop structure seems canonical (Al-Lazikani et al., 1997), the tip of V L CDR2 exhibits a concentration of negatively charged amino acids (Fig. 4b) -four residues 50 DDED 53 at the tip form a hairpin-like turn conformation, which compactly wraps and constrains these four negative charges together. Figure 4b depicts the calculated surface charge distribution on the structural model. The heavily negatively charged surface area around V L CDR2 led us to speculate that the tip of V L CDR2 might be a labile region on the antibody due to significant ionic repulsion.
From the structural analysis, we hypothesized that the highly negatively charged region DDED in V L CDR2 is associated with poor expression. The equivalent residues in Ab008 are DDGD. It is possible that residue G52D change has a bearing on expression differences observed. Firstly, we determined whether the suspected motif (four consecutive charges concentrated on V L CDR2) has ever been observed in any known antibody structure. We searched an antibody database curated from the Protein Data Bank (PDB) by Biovia Discovery Studio and inspected all of the V L CDR2 sequences of 3118 structures deposited before 2015 (sequence redundancy exists). We did not find any antibody sequences whose V L CDR2 exhibited four consecutive charged residues at the relevant positions and so decided to look for such motifs in our internal antibody sequence database, which contains predominantly scFv heavy-and light-chain sequences from phage display selection experiments using our human libraries. From a total of 783 023 unique light-chain sequences of varying sequencing quality, we found only 67 distinct sequences containing 50 DDEX 53 (where X is any amino acid) after manual filtering for quality and uniqueness. Of these we found the following substitution counts for different amino acids in position 53: D15, S1, R2, K2, G10, E32, L1, A1, T3. There is . Two reversion mutants, M27I and E52G, exhibited significantly higher expression than Ab001. Asterisks indicate clones with significantly higher expression than Ab001; *P < 0.05, **P < 0.01 according to the two-tailed unpaired t-test. All experiments were performed in duplicate.
no significantly dominant substitution at position 53 of these very rare 50 DDEX 53 motifs. However, similar sequences such as 50 ADDE 53 , 50 DDND 53 and 50 EDSE 53 were occasionally observed in which one of the four residues in the sequence is neutral. Therefore, we asked whether any of the four residues in the 50 DDED 53 sequence could be replaced by a neutral amino acid in Ab001. To minimize any potential impact on antigen binding, we chose Asn for the substitution because it is the most similar amino acid to Asp yet has no charge at physiologically relevant conditions. We employed Biovia Discovery Studio to simulate the effects of changing each of the four positions on V L CDR2 to Asn and estimated the free energy difference in terms of protein stability (Table III) . Three of the single Asn mutations in 50 DDED 53 (D50N, D51N and D53N ) were predicted to 'stabilize' the structure, whereas E52N was predicted to have a 'neutral' effect. Of the three variants, D53N was predicted to be most stabilizing. DSF calculations of T m (Table II) showed no significant change in thermostability of these variants, however, indicating that if these stabilizing effects are present, they contribute only minimally to the overall thermodynamic stability of the antibodies.
MD analysis of charged V L CDR2
We used MD to assess the range of motions in V L CDR2 upon introduction of an Asn residue. Furthermore, we also analyzed formation of new interactions, effects of charge stress and possible antibody unfolding. In previous computational experiments, where we simulated the effects of changing all Asp in 50 DDED 53 to Asn, D53N had most stabilizing effect upon changing from Asp to Asn.
To explore these details, we chose the Ab001 light chain and its D53N mutant as two comparative systems and performed MD simulations on the light chain. The cartoon representations of the antibody light chains are the snapshots selected from the simulations. Figure 5 shows two representative snapshots drawn from each simulation trajectory. To maintain the secondary structure of V L CDR2, the wild-type 50 DDED 53 residues must rotate all of their side chains 180°t owards the outside of the molecule to reduce the inter-residue ionic interactions that are constrained in the structure. The substitution of charged D53N, however, seems to effectively relieve the charge repulsions on the tip of V L CDR2. Given these observations, we wanted to assess whether the unfolding of Ab001 V L could be causing the antibody to be unstable, thereby leading to low expression levels. However, because the time scale of protein unfolding in vitro can be challenging for regular MD to achieve, we performed another set of simulations, this time under heat stress environment (500 K), to predict which antibody has the most heat-resistant secondary structure against strong thermal perturbations. Figure 5 shows the structural changes in V L CDR2 that were predicted by computing the root mean square deviations (RMSDs) to their respective starting configuration. As expected, the V L CDR2 loop of the wild-type ( 50 DDED 53 ) system unfolded much faster than that of the mutant ( 50 DDEN 53 ) (Fig. 5) . These results suggest that this loop could indeed be the trigger for antibody unfolding, and that a D53N substitution could potentially improve structural stability, delay antibody unfolding and lead to higher expression levels.
Structural studies and mutagenesis identify residues that improve expression
To experimentally test the charge-related computational hypotheses outlined above, we generated a series of mutants (D51N, E52N and  D53N ) and tested their impact on expression in transiently transfected CHO cells (Fig. 6a) . All three antibodies showed significantly higher A 'stabilizing' effect was defined as ΔΔG < −0.5 kcal/mol, and a 'neutral' effect was defined as −0.5 < ΔΔG < 0.5 kcal/mol. expression levels than Ab001 (P < 0.001 Tukey's test). The D53N mutation exhibited the greatest improvement of~2.7-fold, reaching a higher expression level than Ab008 (P < 0.001 Tukey's test). We also combined the two mutagenesis-variants with the highest expression levels (E52G and M27I) to see if in combination they increased expression (Fig. 6a) . There was no significant increase in expression between single reversion E52G antibodies and double reversion M27I E52G antibodies (P = 0.29 Tukey's test). However, when the M27I reversion mutation was combined with a charge-related mutation at position 52 (E52N), there was a significant increase in expression over the double reversion mutant (P < 0.001 Tukey' test) and indeed this antibody had an equivalent expression level to AB008 (P = 0.50 Tukey's test). We did not combine mutation D53N with M27I or E52G, as D53N had already rescued expression levels back to those of parental Ab008 and so was already suitable for potential further development as a therapeutic.
In stable cell lines, a marked increase in expression levels was also observed (Fig. 6b) , with an improvement of 25-fold for the D53N mutation relative to Ab001. All mutants except E52N exhibited improved expression compared with unmodified Ab001 V L (DDND < Ab001 < DDND < E52G < M27I/E52N < M27I/E52G < DDEN). Using structure-guided design, we have therefore been able to increase expression levels back to and beyond the Ab001 levels, with as little as one amino-acid substitution.
In vitro potency of antibodies remains largely unaffected
We next tested whether the potency of mutants D51N, E52N and D53N antibodies had been adversely affected by the mutagenesis and rational design processes described above. The potency of the antibody mutants was tested in three independent TF1 proliferation experiments using human IL-13. A fixed concentration of human IL-13 was used, corresponding to the predetermined EC80 value in each assay. The antibodies were titrated and assessed for their ability to inhibit TF1 proliferation (Fig. 7 ). All antibody variants were able to inhibit the IL-13-driven proliferation, with the exception of the DNED variant and the isotype control (Fig. 7) . The potency of the structure-guided mutants is within 2-fold of Ab001.
Discussion
The aim of this study was to find a method to improve expression levels of Ab008. The methodology developed for identifying problematic residues that affect expression and ultimately impair manufacturing yields could be applied to other examples of proteins with challenging expression. In the example presented here, we have improved the expression of an antibody in transient and stable cell lines while maintaining its high affinity to the antigen. We have applied two existing approaches to improve antibody expression: first, changing a number of resides to those present in the higher expressing Ab008 antibody, and second, analyzing the protein structure and using MD to rationally design various mutants. Although some improvements in expression were made empirically by changing the aminoacid sequence of Ab001 to that of Ab008, we had to use a structural model-based design approach to further enhance expression. A homology model of the Fv highlighted that the V L CDR2 loop had a string of negatively charged residues at its tip ( 50 DDED 53 ). We hypothesized that this may reduce the stability of the V L CDR2 loop and thus contribute to the reduced expression of the antibody. Replacing one or more of the negatively charged residues with a neutral amino acid may confer more stability in the V L CDR2 and, in turn, improve the expression of the antibody. Therefore, we chose to mutate charged Asp residues to neutral Asn in the 50 DDED 53 V L CDR2 loop. Interestingly, all but one of the variants retained their potency. We believe that this loss in potency for variant DNED is due to N51 playing a key role in Ab001 binding to the antigen. Introducing Asn to replace any of the charged residues in this motif enhanced structural stability and exhibited an improvement in the expression level. The introduced N53 (DDEN) residue has the capability to rotate its side chain inside to form hydrogen bonds with backbone atoms of neighboring residues, which would further stabilize the V L CDR2 loop. Analysis of residues surrounding V L CDR2 shows that there are no important interactions between V L CDR2 DDEN and residues in V L CDR1 and framework Synergistic expression improvements were observed when the M27I reversion mutant was combined with either E52G (reversion mutant) or E52N (structural design mutant). All mutants exhibited improved expression compared with unmodified Ab001 V L . (b) Stable expression testing of variants with the sMCA. Synergistic expression improvements were observed when the M27I reversion mutant was combined with either E52G (reversion mutant) or E52N (structural design mutant). All experiments were performed in biological replicates of n = 3 except for sMCA and E52N, which were performed in biological replicates of n = 2.
residues. The D53N mutation, being outside of the nine amino acids that were preferentially selected for during the affinity maturation of Ab008 to Ab001, would obviously not be identified by simply following the initial mutation reversion strategy, highlighting the value of the structural modeling approach which led to its identification. Indeed this single amino-acid mutation resulted in the expression levels that were at least as high as Ab001. In order to minimize the number of mutations from human antibody germline variable domain sequence introduced into this potential human therapeutic antibody, we did not generate combinations of D53N with the other improved mutants E52G or M27I, although it would be interesting to observe whether further increases to expression level would result. Our analysis of sequence and structure databases highlights that the DDED combination of negatively charged residues in V L CDR2 is rarely observed. Methods for experimental studies of protein structure require large amounts of protein to be expressed and so entries in these databases are necessarily biased towards stable structures. Interestingly, none of the antibody structures deposited to PDB have DDED sequence motifs; however, related sequence motifs are present. When relating sequence data to the expression profiles of various in-house antibody sequences, we did not observe a correlation between the DDED motif and poor expression (data not shown). The mutagenesis strategy employed in the affinity maturation of Ab008 to Ab001 involved generating phage libraries of variants with overlapping blocks of up to 6 sequential amino acids mutated to any of the 20 common amino acids (Groves et al., 2014) . Thus, the unusual DDED motif introduced into Ab001 may represent an artefactual 'non-natural' structure borne out of the mutagenesis methodology employed here and may not be representative of likely structural solutions arising from natural in vivo somatic hypermutation. Nonetheless, these types of in vitro affinity maturation approaches are increasingly used during the development of high affinity therapeutic monoclonal antibodies (Lowe et al., 2011) . In this case study, we have demonstrated that this motif was either directly or indirectly, via various aspects of the expression machinery, contributing to the relatively low expression levels of Ab001.
To our knowledge, this is one of only a few examples of the rational design approach being utilized to overcome expression challenges in antibody manufacturing. Previous work describes computational approaches based on heuristic sequence analysis to systematically optimize antibody protein sequences and improve antibody biophysical properties and stability (Seeliger et al., 2015) .
In this report, we use computational strategies based on modeled protein structure analyses, such as surface electrostatics and protein dynamics analyses. Using these structure-guided design strategies, we identified a limited number of specific mutations, one of which, D53N, was sufficient to improve the expression of the antibody back to parental levels. Moreover, the antibody retained its ability to bind to the target antigen with equivalent potency and specificity. For this approach to be successful, however, a thorough understanding of antibody structure and function is required for rational antibody design to improve properties related to developability.
We have shown how a structural modeling-based design strategy can be used to increase antibody expression. We anticipate that this methodology may be generally applicable for addressing expression challenges with other antibodies and proteins. Fig. 7 TF1 proliferation assay testing the ability of anti-IL-13 antibody mutants to inhibit IL-13-driven proliferation. Each line represents the titration curve for a single antibody species, and each data point represents a mean ± SD of assay duplicates. Representative data from a single experiment is presented from a series of three independent experiments. CPM, counts per minute.
